The Navigator Company (NVG) Q3 2024 earnings summary

Executive summary

• Turnover reached €1,569 million for the first nine months of 2024, up 7% year-over-year, with EBITDA at €431 million (+15%) and net profit at €241 million (+20%), driven by strong tissue and packaging performance and resilient pricing.

• Significant cash cost reductions of 4–12% year-over-year across all segments supported margins and profitability.

• Strategic diversification included the acquisition and integration of Accrol (Navigator Tissue UK) and the launch of the world's largest integrated eucalyptus fibre moulded pulp packaging unit.

• Maintained conservative financial policies, with Net Debt/EBITDA at 1.16x and ample liquidity, despite increased capex and M&A activity.

Financial highlights

• EBITDA margin improved to 27.5% (+1.7 pp year-over-year); Q3 EBITDA was €133 million with a margin of 26.3%.

• Capex totaled €151 million, with 53% allocated to ESG and sustainability projects.

• Free cash flow for 9M was negative (€-3 million), mainly due to Accrol acquisition and dividend outflows.

• Net debt increased by €153 million year-over-year, mainly due to Accrol acquisition and €150 million in dividends.

Outlook and guidance

• Q4 began with geopolitical and macroeconomic uncertainty, but sector forecasts remain cautiously optimistic.

• Pulp prices in China expected to recover, with positive price pressure from Latin American capacity cuts and maintenance shutdowns.

• Paper and packaging segments anticipate strong seasonal demand and further capacity reductions in Europe and the US to support prices.

• Tissue demand in Europe projected to grow 5–6% in 2024, with synergies from recent acquisitions.